Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) traded up 10.5% during trading on Tuesday . The stock traded as high as $9.50 and last traded at $9.13. 2,276,502 shares changed hands during mid-day trading, an increase of 124% from the average session volume of 1,018,064 shares. The stock had previously closed at $8.26.
Several analysts have commented on the stock. Raymond James upgraded shares of Amneal Pharmaceuticals from a “market perform” rating to a “strong-buy” rating and set a $13.00 price target on the stock in a research note on Tuesday. They noted that the move was a valuation call. ValuEngine upgraded shares of Amneal Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, May 7th. BMO Capital Markets decreased their price target on shares of Amneal Pharmaceuticals from $14.00 to $13.00 and set a “market perform” rating on the stock in a research note on Friday, May 10th. Zacks Investment Research upgraded shares of Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 8th. Finally, SunTrust Banks assumed coverage on shares of Amneal Pharmaceuticals in a research note on Tuesday, March 19th. They issued a “buy” rating and a $16.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $19.60.
The company has a debt-to-equity ratio of 3.44, a quick ratio of 1.37 and a current ratio of 2.11. The stock has a market cap of $2.73 billion, a PE ratio of 8.68, a PEG ratio of 0.54 and a beta of 1.31.
In other Amneal Pharmaceuticals news, VP Andrew S. Boyer bought 19,000 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were purchased at an average cost of $9.46 per share, for a total transaction of $179,740.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Peter R. Terreri sold 23,345 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $12.39, for a total transaction of $289,244.55. The disclosure for this sale can be found here. Insiders have bought a total of 58,000 shares of company stock worth $590,790 over the last 90 days. Corporate insiders own 26.34% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Cresset Asset Management LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 1st quarter valued at about $29,000. Bessemer Group Inc. purchased a new stake in Amneal Pharmaceuticals in the 4th quarter worth about $34,000. NumerixS Investment Technologies Inc raised its position in Amneal Pharmaceuticals by 52.1% in the 1st quarter. NumerixS Investment Technologies Inc now owns 3,052 shares of the company’s stock worth $42,000 after purchasing an additional 1,045 shares during the period. Quantamental Technologies LLC purchased a new stake in Amneal Pharmaceuticals in the 4th quarter worth about $68,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Amneal Pharmaceuticals by 28.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,700 shares of the company’s stock worth $91,000 after purchasing an additional 1,477 shares during the period. Hedge funds and other institutional investors own 37.81% of the company’s stock.
Amneal Pharmaceuticals Company Profile (NYSE:AMRX)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Recommended Story: Dividend Aristocrat Index
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.